Advertisement
Advertisement
VTGN
Vistagen Therapeutics, Inc. Common Stock
0.25
USDSponsored
+0.02
+7.90%
Sep 22, 15:59 UTC -4
Closed
After-Market
0.25
0.00
-0.56%
VTGN Earnings Reports
Positive Surprise Ratio
VTGN beat 21 of 40 last estimates.
53%
Next Report
Date of Next Report
Nov 11, 2026
Estimate for Q2 27 (Revenue/ EPS)
$255.00K
/-$0.38
Implied change from Q1 27 (Revenue/ EPS)
-82.72%
/+26.67%
Implied change from Q2 26 (Revenue/ EPS)
-1.16%
/-29.63%
Vistagen Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 14, 2026, VTGN reported earnings of -0.30 USD per share (EPS) for Q1 27, beating the estimate of -0.37 USD, resulting in a 20.51% surprise. Revenue reached 1.48 million, compared to an expected 255.00 thousand, with a 478.82% difference. The market reacted with a +0.49% price change (close before vs. close after earnings).
Looking ahead to Q2 27, 6 analysts forecast an EPS of -0.38 USD, with revenue projected to reach 255.00 thousand USD, implying an increase of 26.67% EPS, and decrease of -82.72% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
FAQ
What were Vistagen Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2027?
For Q1 2027, Vistagen Therapeutics, Inc. Common Stock reported EPS of -$0.30, beating estimates by 20.51%, and revenue of $1.48M, 478.82% above expectations.
How did the market react to Vistagen Therapeutics, Inc. Common Stock's Q1 2027 earnings?
The stock price moved up 0.49%, changed from $0.27 before the earnings release to $0.27 the day after.
When is Vistagen Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 11, 2026.
What are the forecasts for Vistagen Therapeutics, Inc. Common Stock's next earnings report?
Based on 6
analysts, Vistagen Therapeutics, Inc. Common Stock is expected to report EPS of -$0.38 and revenue of $255.00K for Q2 2027.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.